TLX
Telix Pharmaceuticals Limited
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+20/100
Last price
11.06
▲ 0.28 (2.55%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.58
Prev close
10.78
Day high
11.08
Day low
11.01
Volume
178.19K
Market cap
$3.76B
P/E (TTM)
110.55
52W range
6.28 – 13.11
Day trading desk
Gap from prior close
-1.86%
Prior close 10.78
VWAP
11.05
+0.02% from price
Relative volume
0.72×
Normal
Session range
6.15%
10.58 – 11.23
Position in range
73%
Near session high
ATR (14D)
0.48
4.32% of price
Prior day high
10.96
PDH
Prior day low
10.73
PDL
Bid / ask spread
—
Quote not published
Session volume
178.12K
Avg 248.69K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+0.77%
-1.2%
1M
-7.72%
-9.2%
3M
-6.15%
-9.6%
6M
+13.04%
-2.0%
YTD
+47.60%
+33.6%
1Y
+8.60%
-7.2%
3Y
—
-82.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TLX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$3.76B
Enterprise value$3.99B
Revenue (TTM)$890.79M
Gross profit$423.71M
EBITDA$69.81M
Net income$33.50M
EPS (TTM)$0.10
Free cash flow$-62.60M
Total cash$251.91M
Total debt$579.86M
Book value / share$1.44
Shares outstanding339.78M
Float273.61M
Short % of float0.11%
Dividend yield0.00%
Beta (5Y)0.56
Valuation & profitability ratios
Trailing P/E110.55
Forward P/E-412.16
PEG ratio—
Price / sales—
Price / book7.70
EV / revenue4.48
EV / EBITDA57.17
Gross margin47.57%
Operating margin9.71%
Profit margin3.76%
Return on equity7.36%
Return on assets2.71%
Debt / equity118.90
Current ratio2.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $803.79M | $516.55M | $332.98M | $108.91M | +55.6% |
| Operating revenue | $803.79M | $516.55M | $332.98M | $108.91M | +55.6% |
| Cost of revenue | $377.36M | $180.39M | $123.44M | $44.34M | +109.2% |
| Gross profit | $426.44M | $336.16M | $209.53M | $64.58M | +26.9% |
| Research & development | $171.25M | $127.93M | $85.31M | $54.89M | +33.9% |
| Selling, general & admin | $237.15M | $152.19M | $89.38M | $59.47M | +55.8% |
| Total operating expense | $408.38M | $280.58M | $174.57M | $115.05M | +45.6% |
| Operating income | $18.05M | $55.58M | $34.97M | -$50.48M | -67.5% |
| Net interest income | -$35.04M | -$17.26M | -$8.41M | -$4.55M | -103.0% |
| Pre-tax income | -$5.27M | $37.91M | $2.59M | -$98.62M | -113.9% |
| Tax provision | $1.86M | $4.23M | -$1.61M | $5.46M | -56.1% |
| Net income | -$7.13M | $33.69M | $4.21M | -$104.08M | -121.2% |
| Net income to common | -$7.13M | $33.69M | $4.21M | -$104.08M | -121.2% |
| Basic EPS | -0.02 | 0.10 | 0.01 | -0.23 | -120.7% |
| Diluted EPS | -0.02 | 0.10 | 0.01 | -0.34 | -121.6% |
| EBIT | $35.15M | $62.06M | $11.54M | -$62.60M | -43.4% |
| EBITDA | $35.15M | $62.06M | $11.54M | -$62.60M | -43.4% |
| Basic shares | 319.18M | 331.23M | 319.18M | 310.64M | -3.6% |
| Diluted shares | 323.71M | 345.19M | 319.18M | 310.64M | -6.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $141.87M | $440.00M | $84.30M | $116.33M | — | -67.8% |
| Cash & short-term investments | $141.87M | $440.00M | $84.30M | $116.33M | — | -67.8% |
| Accounts receivable | $129.20M | $86.93M | $44.04M | $39.35M | — | +48.6% |
| Inventory | $37.08M | $23.62M | $12.74M | $8.48M | — | +57.0% |
| Total current assets | $330.28M | $570.12M | $158.69M | $173.23M | — | -42.1% |
| Property, plant & equipment | $115.61M | $33.65M | $20.86M | $18.84M | — | +243.6% |
| Goodwill & intangibles | $592.82M | $257.86M | $75.05M | $58.98M | — | +129.9% |
| Total assets | $1.16B | $940.38M | $277.26M | $173.72M | — | +23.8% |
| Total current liabilities | $231.62M | $205.09M | $111.37M | $58.20M | — | +12.9% |
| Current debt | $13.11M | $11.76M | $660.00K | — | $13.77K | +11.5% |
| Long-term debt | $391.91M | $341.81M | $5.95M | $2.25M | — | +14.7% |
| Total debt | $467.11M | $360.16M | $12.26M | $10.45M | — | +29.7% |
| Total liabilities | $748.61M | $587.44M | $174.61M | $175.35M | — | +27.4% |
| Retained earnings | -$154.54M | -$152.91M | -$187.12M | -$272.81M | — | -1.1% |
| Shareholder equity | $415.38M | $352.94M | $102.64M | $54.43M | — | +17.7% |
| Working capital | $98.66M | $365.03M | $47.32M | $87.68M | — | -73.0% |
| Net tangible assets | -$177.45M | $95.08M | $27.59M | $14.30M | — | -286.6% |
| Shares issued | 338.78M | 334.72M | 323.73M | 316.34M | — | +1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Capital expenditure | -$43.78M | -$22.18M | -$7.11M | -$9.43M | -97.3% |
| Investing cash flow | -$285.92M | -$86.69M | -$16.84M | -$17.00M | -229.8% |
| Share buybacks | — | — | — | -$7.82M | — |
| Financing cash flow | -$3.72M | $416.79M | $7.09M | $119.03M | -100.9% |
| Free cash flow | -$61.07M | $5.31M | $7.16M | -$77.83M | -1,250.9% |
| End cash position | $141.87M | $440.00M | $84.30M | $79.14M | -67.8% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
| Line item | 2026-06-30 | 2025-12-31 | 2025-06-30 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $251.91M | $141.87M | $207.16M | +77.6% |
| Cash & short-term investments | $251.91M | $141.87M | $207.16M | +77.6% |
| Accounts receivable | $163.56M | $129.20M | — | +26.6% |
| Inventory | $39.03M | $37.08M | — | +5.3% |
| Total current assets | $488.02M | $330.28M | — | +47.8% |
| Property, plant & equipment | $129.63M | $115.61M | — | +12.1% |
| Goodwill & intangibles | $584.61M | $592.82M | — | -1.4% |
| Total assets | $1.36B | $1.16B | — | +17.0% |
| Total current liabilities | $242.34M | $231.62M | $298.58M | +4.6% |
| Current debt | $11.51M | $13.11M | $12.69M | -12.2% |
| Long-term debt | $504.88M | $391.91M | — | +28.8% |
| Total debt | $579.86M | $467.11M | — | +24.1% |
| Total liabilities | $874.18M | $748.61M | $768.01M | +16.8% |
| Retained earnings | -$110.90M | -$154.54M | -$150.98M | +28.2% |
| Shareholder equity | $487.68M | $415.38M | $421.94M | +17.4% |
| Working capital | $245.68M | $98.66M | — | +149.0% |
| Net tangible assets | -$96.94M | -$177.45M | -$162.23M | +45.4% |
| Shares issued | 338.78M | 338.78M | 334.72M | 0.0% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.00 | — | — |
| Dec 2025 | 0.08 | — | — |
| Sep 2025 | -0.14 | — | — |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.07 | 1 | $312.02M | -1.8% |
| Next quarter | 0.07 | 1 | $310.00M | +0.1% |
| Current year | 0.15 | 5 | $1.39B | +15.9% |
| Next year | -0.04 | 2 | $1.58B | +13.9% |
Analyst targets & ownership
Mean target$20.42
High target$22.15
Low target$18.00
Implied upside84.68%
Analyst count4
ConsensusSTRONG BUY
Strong buy / Buy0 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.98%
Institutions holding74
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.07
-0.11% from price
SMA 20
11.50
-3.84% from price
SMA 50
11.42
-3.16% from price
SMA 100
10.87
+1.68% from price
SMA 200
9.70
+14.02% from price
EMA 12
11.14
-0.72% from price
EMA 26
11.34
-2.51% from price
EMA 50
11.30
-2.15% from price
RSI (14)
46.9
Neutral
MACD (12,26,9)
-0.20
Hist -0.10
ATR (14)
0.48
4.32% of price
Realised vol 30D
67.2%
Annualised
Bollinger upper
12.73
20, 2σ
Bollinger lower
10.26
20, 2σ
50 / 200 cross
Golden
11.42 vs 9.70
Trend bias
Above 200
+14.02%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.99
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
67.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.8%
Peak to trough
Max drawdown 5Y
-69.4%
Peak to trough
ATR 14
0.48
4.32% of price
Beta (reported)
0.56
5Y monthly, from filing
Short interest
Shares short
352.52K
Prior 244.90K
Change vs prior
+43.9%
Shorts adding
% of float
0.11%
Normal
% of shares out
0.10%
Against total outstanding
Days to cover
1.3
Liquid
Float
273.61M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 23, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 15, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 14, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Jul 7, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 7, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 13, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Apr 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 7, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-09-30
Corporate Changes & Voting Matters
6-K · 2026-09-21
Corporate Changes & Voting Matters
6-K · 2026-09-14
Corporate Changes & Voting Matters
6-K · 2026-09-02
Corporate Changes & Voting Matters
6-K · 2026-09-01
Corporate Changes & Voting Matters
6-K · 2026-08-20
Corporate Changes & Voting Matters
6-K · 2026-07-21
Corporate Changes & Voting Matters
6-K · 2026-07-02
Headlines
Telix Doses First US Patients With FDA-Approved Brain Cancer Imaging Drug
MT Newswires · 1d ago
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
GlobeNewswire · 1d ago
Wall Street Analysts Believe Telix Pharmaceuticals Limited (TLX) Could Rally 83.42%: Here's is How to Trade
Zacks · 7d ago
Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging
PR Newswire · 8d ago
3 Australian Growth Stocks With Earnings Growth Up To 65%
Simply Wall St. · 11d ago
Telix (ASX:TLX) Shares Could Be 42% Undervalued Following Its ITM Deal
Simply Wall St. · 14d ago
Telix Pharmaceuticals (ASX:TLX) ITM Deal Puts Valuation Back In Focus
Simply Wall St. · 14d ago
Telix (TLX) to Buy Germany’s ITM for up to $2.35 Billion to Lock in its Cancer Isotope Supply
Insider Monkey · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.